Literature DB >> 6255011

Immunoreactive beta-endorphin and adrenocorticotropin in human cerebrospinal fluid.

K Nakao, S Oki, I Tanaka, K Horii, Y Nakai, T Furui, M Fukushima, A Kuwayama, N Kageyama, H Imura.   

Abstract

To elucidate the significance of beta-endorphin in human cerebrospinal fluid (CSF), CSF levels of beta-endorphin-like immunoreactivity (beta-EP-LI) in various diseases were determined by a specific radioimmunoassay and compared with simultaneously determined ACTH-like immunoreactivity (ACTH-LI) levels in CSF. CSF beta-EP-LI and ACTH-LI in the control group, consisting of 5 normal subjects and 19 patients with nonendocrine diseases, were 22.2+/-1.3 and 14.6+/-0.4 fmol/ml, respectively. CSF levels of these peptides in patients with schizophrenia (n = 19) and acromegaly (n = 10) were not significantly different from those in the control group. Patients with Cushing's disease (n = 7) had significantly lower CSF beta-EP-LI and ACTH-LI levels than those in the control group. Four of them showed a parallel increase in CSF beta-EP-LI and CSF ACTH-LI levels after the complete removal of pituitary microadenomas (P < 0.05). Gel chromatography of CSF beta-EP-LI from a normal volunteer, a control patient, and one patient each with catatonia, Nelson's syndrome, Cushing's syndrome (adrenal adenoma), and acromegaly gave similar patterns consisting of three peaks with the elution positions comparable to those of authentic beta-endorphin, beta-lipotropin, and possibly their precursor molecule. Gel chromatographic patterns of CSF beta-EP-LI and ACTH-LI were compared in a normal volunteer. The first peaks of beta-EP-LI and ACTH-LI eluted at the same position and the second peak of ACTH-LI coincided with the elution position of authentic ACTH.CSF beta-EP-LI and ACTH-LI levels determined every 5 min over a period of 80 min in three normal volunteers did not show moment-to-moment variability.A significant correlation (r = 0.75, P < 0.001) was seen between CSF beta-EP-LI and ACTH-LI levels in normal subjects and patients studied (n = 73). This suggests that beta-endorphin and ACTH in human CSF share the common regulatory mechanism in normal and pathologic conditions.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6255011      PMCID: PMC371624          DOI: 10.1172/JCI109991

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  35 in total

1.  Endorphins: profound behavioral effects in rats suggest new etiological factors in mental illness.

Authors:  F Bloom; D Segal; N Ling; R Guillemin
Journal:  Science       Date:  1976-11-05       Impact factor: 47.728

2.  Lack of effect on naloxone on schizophrenic symptoms.

Authors:  D S Janowsky; D S Segal; F Bloom; A Abrams; R Guillemin
Journal:  Am J Psychiatry       Date:  1977-08       Impact factor: 18.112

3.  beta-endorphin is a potent analgesic agent.

Authors:  H H Loh; L F Tseng; E Wei; C H Li
Journal:  Proc Natl Acad Sci U S A       Date:  1976-08       Impact factor: 11.205

4.  beta-Endorphin: behavioral and analgesic activity in cats.

Authors:  M Meglio; Y Hosobuchi; H H Loh; J E Adams; C H Li
Journal:  Proc Natl Acad Sci U S A       Date:  1977-02       Impact factor: 11.205

5.  Corticotrophin in cerebrospinal fluid of patients with Nelson's syndrome.

Authors:  M Kleerekoper; R A Donald; S Posen
Journal:  Lancet       Date:  1972-01-08       Impact factor: 79.321

6.  Radioimmunoassay of ACTH in plasma.

Authors:  S A Berson; R S Yalow
Journal:  J Clin Invest       Date:  1968-12       Impact factor: 14.808

7.  Naloxone in chronic schizophrenia.

Authors:  J Volavka; A Mallya; S Baig; J Perez-Cruet
Journal:  Science       Date:  1977-06-10       Impact factor: 47.728

8.  Naloxone-induced reversal of schizophrenic hallucinations.

Authors:  L M Gunne; L Lindström; L Terenius
Journal:  J Neural Transm       Date:  1977       Impact factor: 3.575

9.  Intravenous naloxone administration in schizophrenia and affective illness.

Authors:  G C Davis; W E Bunney; E G DeFraites; J E Kleinman; D P van Kammen; R M Post; R J Wyatt
Journal:  Science       Date:  1977-07-01       Impact factor: 47.728

10.  Common precursor to corticotropins and endorphins.

Authors:  R E Mains; B A Eipper; N Ling
Journal:  Proc Natl Acad Sci U S A       Date:  1977-07       Impact factor: 11.205

View more
  7 in total

1.  CSF beta-endorphin and leu-enkephalin levels in the acute and chronic stages of cerebral infarction.

Authors:  M Kobari; N Ishihara; K Yunoki
Journal:  J Neurol       Date:  1987-06       Impact factor: 4.849

Review 2.  Distribution of beta-endorphin-related peptides in rat pituitary and brain.

Authors:  S Zakarian; D G Smyth
Journal:  Biochem J       Date:  1982-03-15       Impact factor: 3.857

3.  Dissociation between CSF and plasma B-endorphin in major depressive disorders: evidence for a different regulation.

Authors:  F Facchinetti; F Petraglia; G Sances; C Garuti; P Tosca; G Nappi; A R Genazzani
Journal:  J Endocrinol Invest       Date:  1986-02       Impact factor: 4.256

4.  Immunoreactive beta-endorphin levels in cerebrospinal fluid of children with acute lymphoblastic leukemia: relationship with glucocorticoid therapy and neurological complications.

Authors:  P Iannetti; A Fabbri; G Meloni; M L Moleti; S Ulisse; F Mandelli; A Isidori; C Imperato
Journal:  J Endocrinol Invest       Date:  1989-10       Impact factor: 4.256

5.  Non-suicidal self-injurious behavior, endogenous opioids and monoamine neurotransmitters.

Authors:  Barbara Stanley; Leo Sher; Scott Wilson; Rolf Ekman; Yung-yu Huang; J John Mann
Journal:  J Affect Disord       Date:  2009-11-25       Impact factor: 4.839

Review 6.  Biosynthesis and distribution of opioid peptides.

Authors:  H Imura; Y Nakai; K Nakao; S Oki; I Tanaka; H Jingami; T Yoshimasa; T Tsukada; Y Ikeda; M Suda; M Sakamoto
Journal:  J Endocrinol Invest       Date:  1983-04       Impact factor: 4.256

Review 7.  Translational science: Newly emerging science in biology and medicine - Lessons from translational research on the natriuretic peptide family and leptin.

Authors:  Kazuwa Nakao
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2019       Impact factor: 3.493

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.